T-DXd for Advanced HER2-Positive or HER2-Low Breast Cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is studying a drug called T-DXd (trastuzumab deruxtecan) for Chinese women with advanced breast cancer that has a certain protein (HER2) either in high or low amounts. It aims to see how well the drug works in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older with advanced breast cancer that has spread or cannot be removed by surgery.
- Your cancer must be HER2-positive (overexpressing) or HER2-low (underexpressing) as confirmed by a special test.
- You have at least one tumor that can be measured on a scan.
- You are not pregnant or breastfeeding.
- You may have had other treatments for advanced breast cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
This trial tests a drug called T-DXd (a targeted chemotherapy) combined with hormone therapy for people with HER2-positive and hormone receptor-positive advanced breast cancer who have not had prior treatment for their metastatic disease. It includes an upfront phase, a maintenance phase, and a retreatment phase to see if restarting T-DXd is effective.
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
Hear when a new HER2 Overexpression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.